Adaptive designs include group sequential, sample-size re-estimation, response-adaptive randomization, and adaptive enrichment. Modifications must be pre-specified to preserve Type I error and trial integrity. FDA's 2016 guidance on adaptive designs for medical device clinical studies describes acceptable approaches and expects simulations showing error rates are controlled. Interim analyses are usually performed by an independent statistician or DSMB so the sponsor does not see unblinded results. Adaptive designs can reduce sample size or stop early for success or futility.

Why it matters

FDA actively encourages well-designed adaptive trials, especially in rare-disease and breakthrough device contexts.

Common pitfalls

•Failing to pre-specify adaptation rules can compromise the integrity of the trial and lead to difficulties in regulatory acceptance.
•Inadequate justification for adaptations or poor statistical planning can result in biased outcomes or inflated Type I error rates.
•Overly complex adaptive designs can be difficult to implement and may introduce operational challenges.
•Failure to engage with regulatory bodies early in the planning of an adaptive trial may lead to delays or rejection of study results.
•Ignoring the potential impact of adaptations on blinding or randomization can undermine the validity of the trial.

Sources

FDA - Clinical Trials and Human Subject Protection · FDA
ClinicalTrials.gov · NIH
ICH Guidelines · ICH

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.